IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors
- PMID: 25970604
- DOI: 10.1002/jmv.24227
IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors
Abstract
The single nucleotides polymorphisms analyses in the regions near the IL28B gene in patients chronically infected with genotype 1 hepatitis C virus (HCV) are an important predictive factor for sustained virological response (SVR). The aim was to assess the predictive value of the polymorphisms of the IL28B/IFNL3 gene in patients chronically infected with genotype 1 for the viral clearance obtained after initial treatment including admixed populations. A systematic review was conducted, using a meta-analysis in the PubMed, Embase, LILACS, and SCIELO using MesH and DECS in 42 studies. The parameters were IL28B polymorphisms, rs12979860, rs8099917, and rs12980275, SVR ratio, and OR (odds ratio). OR and confidence Interval of 95% (95%CI), were calculated by fixed or random effects models. Heterogeneity, sensitivity analysis, and publication bias were also performed. Significant differences were noted between carriers groups with the major versus minor allele at rs12979860 CC versus CT/TT-genotype (OR = 4.18; 95%CI = 3.37-5.17), rs8099917 TT versus TG/GG-genotype (OR = 4.07; 95%CI = 2.94-5.63), and rs12980275 AA versus AA/AG-genotype (OR = 5.34; 95%CI = 1.60-17.82). There was selection bias in the rs8099917 analysis (Egger's regression P = 0.049), which reversed after performing a sensitivity analysis (P = 0.510). The incorporation of SNP analyses in IL28B/IFNL3 gene during the diagnosis process in Brazil should be used as a complementary tool to determine the appropriate treatment for HCV genotype 1. Here, we confirm that the rs12979860 CC, rs8099917 TT, and rs12980275 AA genotype-carriers have favorable responses to standard therapy, including two studies with Brazilian population, and this information should be considered.
Keywords: chronic hepatitis C; genotype 1; interleukin 28B; meta-analysis; sustained virological response.
© 2015 Wiley Periodicals, Inc.
Similar articles
-
Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14. Liver Int. 2014. PMID: 24102823
-
Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16. Aliment Pharmacol Ther. 2012. PMID: 22591106
-
Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20. Int J Infect Dis. 2015. PMID: 25462177
-
IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.Clin Res Hepatol Gastroenterol. 2015 Oct;39(5):576-83. doi: 10.1016/j.clinre.2015.01.009. Epub 2015 Mar 10. Clin Res Hepatol Gastroenterol. 2015. PMID: 25769643 Review.
-
The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis.Microb Pathog. 2019 Sep;134:103598. doi: 10.1016/j.micpath.2019.103598. Epub 2019 Jun 12. Microb Pathog. 2019. PMID: 31201901 Review.
Cited by
-
Interferon-λ orchestrates innate and adaptive mucosal immune responses.Nat Rev Immunol. 2019 Oct;19(10):614-625. doi: 10.1038/s41577-019-0182-z. Epub 2019 Jun 14. Nat Rev Immunol. 2019. PMID: 31201377 Review.
-
Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals.Pharmgenomics Pers Med. 2017 Mar 28;10:79-91. doi: 10.2147/PGPM.S125452. eCollection 2017. Pharmgenomics Pers Med. 2017. PMID: 28405170 Free PMC article. Review.
-
Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients.Dis Markers. 2018 Aug 14;2018:2514901. doi: 10.1155/2018/2514901. eCollection 2018. Dis Markers. 2018. PMID: 30186532 Free PMC article.
-
Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism.Gastroenterol Rep (Oxf). 2017 Aug;5(3):208-212. doi: 10.1093/gastro/gow033. Epub 2016 Oct 24. Gastroenterol Rep (Oxf). 2017. PMID: 28852525 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous